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Gs-coupled GPCR signalling in AgRP neurons
triggers sustained increase in food intake
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Adam S. Smith4, Shalini Jain1, Bradford B. Lowell5, Michael J. Krashes2 & Ju¨rgen Wess1
Agouti-related peptide (AgRP) neurons of the hypothalamus play a key role in regulating food
intake and body weight, by releasing three different orexigenic molecules: AgRP; GABA; and
neuropeptide Y. AgRP neurons express various G protein-coupled receptors (GPCRs)
with different coupling properties, including Gs-linked GPCRs. At present, the potential role of
Gs-coupled GPCRs in regulating the activity of AgRP neurons remains unknown. Here we
show that the activation of Gs-coupled receptors expressed by AgRP neurons leads to a
robust and sustained increase in food intake. We also provide detailed mechanistic data
linking the stimulation of this class of receptors to the observed feeding phenotype.
Moreover, we show that this pathway is clearly distinct from other GPCR signalling cascades
that are operative in AgRP neurons. Our data suggest that drugs able to inhibit this signalling
pathway may become useful for the treatment of obesity.
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D
uring the past decades, obesity has emerged as a major
health crisis in most parts of the world1. Obesity
represents a major risk factor for many severe diseases
including type 2 diabetes, cancer and cardiovascular disease, thus
posing an enormous socio-economic burden2.
Given the limited success of behavioural approaches towards
achieving long-lasting weight loss, there is a clear need for
effective pharmacological strategies to stem the current
obesity epidemic3. Unfortunately, the number and efﬁcacy of
appetite-suppressing drugs that have been approved for clinical
use is severely limited3.
To guide the design of novel appetite-suppressing drugs, it is
essential to map the neuronal circuits that regulate food intake
under physiological and pathophysiological conditions. In the
present study, we focused on a small subpopulation of
hypothalamic neurons located in the arcuate nucleus (ARC) of
the hypothalamus, which synthesize and release agouti-related
peptide (AgRP), a neuropeptide endowed with potent,
long-lasting orexigenic activity4. These neurons, which are
generally referred to as AgRP neurons, release two additional
agents that promote acute feeding, neuropeptide Y (NPY) and
GABA, a biogenic amine neurotransmitter4,5. At present, the
relative roles of these three orexigenic agents in stimulating
appetite in response to different hormones or neurotransmitters
are not well understood.
Numerous studies have shown that AgRP neurons play a key
role in regulating food intake and energy homeostasis6–10. For
example, acute ablation of AgRP neurons in adult animals results
in the cessation of feeding and, ultimately, starvation6,7.
As is the case with essentially all other cell types, the activity of
AgRP neurons is predicted to be regulated by cell surface
receptors belonging to the superfamily of G protein-coupled
receptors (GPCRs), which are linked to distinct functional
classes of G proteins11,12. So far, the functional consequences of
activating the various GPCR/G protein signalling pathways in
AgRP neurons have not been studied systematically. To address
this issue, we started to employ a new set of pharmacological tools
referred to as DREADDs (designer receptors exclusively activated
by designer drugs). DREADDs represent mutant muscarinic
acetylcholine receptors that are unable to bind acetylcholine or
any other endogenous ligands13. However, DREADDs can be
selectively activated by clozapine-N-oxide (CNO), a compound
that is otherwise pharmacologically inert13–17. Importantly, we
and others recently developed DREADDs endowed with distinct
coupling G protein properties15–17, making it possible to monitor
the in vivo consequences of activating distinct GPCR signalling
pathways in a drug (CNO)-dependent fashion in speciﬁc cell
types. Such studies are not possible to perform with native
GPCRs, which, as a general rule, are expressed in multiple tissues
and cell types18.
We recently generated mice that selectively express a
Gq-DREADD (hM3Dq; ref. 13) or a Gi-DREADD (hM4Di;
ref. 13) in AgRP neurons of the ARC19. We found that
CNO treatment of these animals resulted in greatly enhanced
or reduced food intake, respectively19. In the present study, we
selectively expressed a Gs-linked DREADD (GsD; ref. 16) in
mouse AgRP neurons. We demonstrate that drug-mediated
stimulation of this receptor in AgRP neurons leads to a sustained
increase in food intake that almost exclusively depends on the
release of AgRP. In addition, we delineate a novel cellular
pathway predicted to underlie this activity and show that this
pathway is clearly distinct from the one involved in triggering
acute food intake via activation of Gq-coupled GPCRs in AgRP
neurons. These new ﬁndings suggest that drugs capable of
reducing Gs signalling in AgRP neurons might become clinically
useful as appetite-suppressing drugs.
Results
Expression of a Gs-coupled DREADD in AgRP neurons. In the
present study, we selectively expressed a Gs-coupled designer
GPCR (Gs DREADD¼GsD) in AgRP neurons of the mouse ARC.
The generation and pharmacological properties of this construct
have been described previously14. The GsD designer receptor, like
other members of the DREADD family13,15–17, is no longer
recognized by endogenous ligands, but can be selectively activated
by CNO, an otherwise pharmacologically inert compound. To
facilitate the detection of GsD expression in the mouse brain, we
fused an enhanced green ﬂuorescent protein (eGFP) tag to the C
terminus of GsD (GsD-eGFP). Studies with transfected COS-7
cells demonstrated that the eGFP tag did not interfere with proper
receptor expression and the ability of CNO to induce
GsD-dependent Gs activation, as measured in cAMP
accumulation assays (Supplementary Table 1).
To selectively express GsD (GsD-eGFP) in mouse AgRP
neurons, we used a Cre-recombinase-dependent adeno-associated
virus (AAV) to target GsD to AgRP neurons. Stable transgene
inversion was achieved by using FLEX Switch technology20.
We stereotaxically injected an AAV that contained the
GsD-eGFP coding sequence in the reverse orientation
(AAV-hSyn-DIO-GsD-eGFP) into the ARC of AgRP-ires-Cre
mice (bilaterally), which selectively express Cre recombinase
in AgRP neurons. To demonstrate the selective expression of
GsD-eGFP by AgRP neurons, we injected the same AAV into the
ARC of AgRP-ires-Cre; R26-loxSTOPlox-L10-GFP mice (L10-GFP
mice)21. In this mouse line, eGFP is selectively expressed, in a
Cre-dependent fashion, in AgRP neurons21. GsD-eGFP
expression was detected by an antibody directed against the
eGFP tag (note that no native GFP ﬂuorescence was observed
with this construct, most likely due to low GsD-eGFP expression
levels). This approach revealed the selective expression of
the GsD-eGFP designer receptor in AgRP neurons of the ARC
(Fig. 1a,b). For brevity, we refer to the AAV-hSyn-DIO-GsD-
eGFP-injected AgRP-ires-Cre mice simply as ‘GsD-AgRP mice’.
For control purposes, we used the same approach to inject
the AAV-hSyn-DIO-hM3Dq-mCherry virus into the ARC of
AgRP-ires-Cre mice19 (note that hM3Dq represents a Gq-coupled
DREADD). We refer to these mice, which express the
hM3Dq designer receptor selectively in AgRP neurons19, as
‘hM3Dq-AgRP mice’ throughout the manuscript. Whole-cell
patch clamp electrophysiological recordings revealed
clear differences in CNO responses between GsD-AgRP and
hM3Dq-AgRP neurons. We previously reported that CNO
rapidly depolarizes the resting membrane potential of
hM3Dq-AgRP neurons (see Fig. 1c, bottom panel, for a
representative trace; see ref. 19). In contrast, bath application of
CNO (10 mM) had no signiﬁcant effect on the membrane
potential of GsD-AgRP neurons (baseline,  44.3±5.5mV;
after CNO,  44.8±5.6mV; n¼ 7; Fig. 1c, top panel, d).
To trigger GsD signalling selectively in mouse AgRP neurons,
we injected GsD-AgRP mice with a single dose of CNO
(1mg kg 1 intraperitoneal (i.p.)) or saline (as a negative control).
Gene expression studies were performed 2 h after CNO injections.
CNO treatment of GsD-AgRP mice had no detectable effect on
c-fos expression in AgRP neurons (Fig. 2b,g and Supplementary
Fig. 1b). GsD activation is predicted to increase cellular
cAMP levels and to stimulate the activity of protein kinase A
(PKA)14,22, resulting in the phosphorylation of many cellular
proteins including the transcription factor CREB. Consistent with
this concept, we found that CNO treatment of GsD-AgRP mice
promoted CREB phosphorylation selectively in AgRP neurons
(Fig. 2a,e and Supplementary Fig. 1a). In contrast, saline-injected
GsD-AgRP mice showed little or no pCREB staining in AgRP
neurons (Fig. 2a,e and Supplementary Fig. 1a). These data clearly
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indicate that the GsD designer receptor is functional in AgRP
neurons.
Interestingly, hM3Dq-AgRP mice displayed a functional proﬁle
that was opposite to that observed with the GsD-AgRP mice.
In hM3Dq-AgRP mice, CNO treatment triggered strong c-fos
staining in hM3Dq-expressing AgRP neurons, while little or no
c-fos expression was observed with saline-treated hM3Dq-AgRP
mice (Fig. 2d,h and Supplementary Fig. 1d; also see ref. 19). In
contrast to GsD-AgRP mice, CNO treatment of hM3Dq-AgRP
mice did not result in a detectable increase in CREB
phosphorylation in AgRP neurons (Fig. 2c,f and Supplementary
Fig. 1c). A quantitative summary of the pCREB and c-fos
expression data is given in Fig. 2e–h.
GsD activation promotes sustained feeding. We next examined
whether GsD signalling in AgRP neurons was able to modulate
food intake. Speciﬁcally, we injected GsD-AgRP mice with a
single dose of CNO (1 mg intracerebroventricular (i.c.v.)) or saline
early in the morning (between 9:00 and 10:00) when mice are
satiated and consume little food. In most feeding experiments, we
delivered CNO i.c.v. since this route of application yielded more
consistent data, as compared with i.p. administration of CNO.
Subsequently, we monitored acute food intake over a 4-h period
as well as long-lasting effects on food intake over the following
3 days. In wild-type (WT) control mice, CNO administration
(1 mg i.c.v.) had no signiﬁcant effect on food intake
(Supplementary Fig. 2). In contrast, CNO treatment of
GsD-AgRP mice triggered a robust increase in food intake
during the ﬁrst 4 h after CNO injection (Fig. 3a). Surprisingly, this
CNO-induced orexigenic effect was very long-lasting (for 3 days;
Fig. 3b). The orexigenic effects of CNO were dose dependent,
as shown in Supplementary Fig. 3. Consistent with the
food intake data, CNO-injected GsD-AgRP mice displayed a
signiﬁcant increase in body weight on days 2 and 3 after CNO
administration (Fig. 3c).
For control purposes, we carried out analogous experiments
with hM3Dq-AgRP mice. As reported previously19, CNO
treatment (1 mg i.c.v.) of hM3Dq-AgRP mice triggered a
striking increase in food intake during the ﬁrst 24 h after CNO
administration (Fig. 3d,e). This effect was even more robust
than that observed with GsD-AgRP mice (please note that the
y axes have different scales in Fig. 3a,d). However, in contrast to
GsD-AgRP mice in which CNO triggered long-lasting orexigenic
effects (Fig. 3b), CNO-treated hM3Dq-AgRP mice showed
normal food intake on days 2 and 3 after CNO injection
(Fig. 3e). In agreement with this observation, CNO-treated
hM3Dq-AgRP mice did not show any changes in body weight on
days 2 and 3 after CNO injection, as compared with saline-treated
hM3Dq-AgRP mice (Fig. 3f).
Previous studies have demonstrated that AgRP treatment of
rodents has long-lasting effects on food intake23,24. We therefore
speculated that the sustained feeding phenotype displayed by the
CNO-injected GsD-AgRP mice was due to GsD-dependent AgRP
release. To address this issue, we injected WT control mice with a
single dose (3 mg i.c.v.) of an active AgRP fragment, AgRP83–132,
using the same experimental set-up as described above. Strikingly,
the AgRP83–132-injected WT mice showed increases in food
intake and body weight that were characterized by a pattern very
similar to that observed with CNO-treated GsD-AgRP mice
(Fig. 3g–i).
GsD-induced feeding requires AgRP release. To further test the
hypothesis that the orexigenic effects observed after activation of
the GsD designer receptor require AgRP, we used two different
experimental strategies.
First, we generated GsD-AgRP mice that carried a single copy
of the agouti ‘lethal yellow’ mutant allele (Ay) (GsD-AgRP, Ay
mice). For comparison, we also introduced the Ay mutation into
hM3Dq-AgRP mice (hM3Dq-AgRP, Ay mice). The Ay mutation
leads to the ectopic expression of agouti protein in the brain
(as well as other tissues) where it blocks central melanocortin
receptors, in a fashion similar to AgRP25. As a result, mice
carrying the Ay mutation are predicted to show reduced
sensitivity to the orexigenic actions of AgRP26. We found that
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Figure 1 | Expression of the GsD designer receptor in AgRP neurons of
the ARC. (a,b) Speciﬁc expression of GsD in AgRP neurons of Agrp-ires-Cre;
R26-loxSTOPlox-L10-GFP mice. In this mouse line, eGFP-L10 is selectively
expressed, in a Cre-dependent fashion, in AgRP neurons21. Mice were
injected unilaterally (right side) into the ARC with the AAV-hSyn-DIO-GsD-
eGFP virus. The GsD designer receptor was detected by using an anti-HA
tag antibody that recognizes the HA tag fused to the N terminus of GsD
(left panels). In the centre panels, AgRP-positive neurons are visualized by
green eGFP ﬂuorescence (from R26-L10-GFP). The right panels represent a
merged image indicating expression of GsD in AgRP neurons (AAV-injected
side only). (b) Higher-magniﬁcation images. Scale bar, 100mm. (c,d) CNO
has no effect on GsD-AgRP neurons in whole-cell patch clamp
electrophysiological recordings. (c) CNO has no signiﬁcant effect on the
membrane potential of GsD-AgRP neurons (GsD-AgRP neurons were
identiﬁed by mCherry ﬂuorescence in AgRP-ires-Cre mice injected with
AAV-hSyn-DIO-rM3D(Gs)-mCherry virus). The upper trace shows a
representative recording from a GsD-AgRP neuron in response to CNO
bath application. For comparison, the lower trace depicts a representative
recording derived from an hM3Dq-AgRP neuron, indicating that CNO
depolarizes hM3Dq-AgRP neurons (also see ref. 19). In this latter
experiment, AgRP-ires-Cre mice were injected with the AAV-hSyn-DIO-
hM3Dq-mCherry virus, which codes for a Gq-coupled DREADD (hM3Dq).
Data are given as means±s.e.m. (n¼ 7 neurons from 4–5 mice).
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CNO failed to stimulate food intake in GsD-AgRP mice carrying
the Ay mutation (Fig. 4a). In contrast, the presence of the Ay
mutation did not interfere with the ability of CNO to promote
robust food intake in hM3Dq-AgRP mice (Fig. 4b), in agreement
with the outcome of a previous study employing optogenetic
interrogation of AgRP neurons26.
Second, we co-injected GsD-AgRP mice with CNO (0.5 mg
i.c.v.) and an anti-AgRP antibody (1 mg i.c.v.)27. Treatment of
GsD-AgRP mice with the anti-AgRP antibody alone had no
signiﬁcant effect on food intake (Supplementary Fig. 4).
Strikingly, the anti-AgRP antibody completely blocked the
ability of CNO to promote food intake in GsD-AgRP mice
(Fig. 4c). In contrast, treatment of hM3Dq-AgRP mice with the
anti-AgRP antibody had no signiﬁcant effect on CNO-mediated
orexigenic effects (Fig. 4d).
These data clearly indicate that the orexigenic effects mediated
by Gs- and Gq-coupled receptors selectively expressed in AgRP
neurons involve different cellular/neuronal mechanisms.
GsD-induced feeding does not require NPY/GABA release. A
recent study5 demonstrated that the acute orexigenic effect
observed with CNO-treated hM3Dq-AgRP mice requires
the release of NPY and/or GABA. We therefore explored
the possibility that NPY or GABA might also contribute to
the CNO-mediated increase in food intake in GsD-AgRP mice.
Initially, we demonstrated that treatment of GsD-AgRP mice
with NPY (0.85 mg i.c.v.) caused a marked increase in food
intake (Supplementary Fig. 5a), consistent with the well-
known orexigenic activity of NPY28. Co-injection of NPY
with BIBO3304 (3 mg i.c.v.), a selective NPY Y1 receptor
antagonist29, completely abolished NPY-induced feeding in
GsD-AgRP mice (Supplementary Fig. 5a), indicating that
the orexigenic effects of NPY are mediated by NPY Y1
receptors. Treatment of control mice (AgRP-ires-Cre mice
that had been injected with AAV-hSyn-DIO-mCherry) with
BIBO3304 alone had no effect on basal food intake
(Supplementary Fig. 5b).
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Figure 2 | The GsD designer receptor selectively promotes pCREB expression in AgRP neurons. (a,b) AAV-mediated functional expression of GsD
(GsD-eGFP) in AgRP neurons. pCREB (a) or c-fos (b) expression in AgRP neurons of GsD-AgRP mice was studied after CNO (1mg kg 1) or saline
(Sal.; control) treatment. Representative confocal images are shown. pCREB and c-fos expression were revealed by anti-pCREB and anti-c-fos antibodies,
respectively (red staining). The GsD receptor was detected by using an anti-GFP antibody that recognized the eGFP tag fused to the C terminus of GsD
(green staining). The images show selective induction of pCREB expression in AgRP neurons of CNO-treated GsD-AgRP mice. (c,d) AAV-mediated
functional expression of hM3Dq (hM3Dq-mCherry) in AgRP neurons. pCREB (c) or c-fos (d) expression in AgRP neurons of hM3Dq-AgRP mice was
studied after CNO (1mg kg 1) or saline (control) treatment. Representative confocal images are shown. pCREB and c-fos expression were revealed by anti-
pCREB and anti-c-fos antibodies, respectively (green staining). The red staining (mCherry ﬂuorescence) visualizes hM3Dq-expressing neurons. The images
show selective induction of c-fos expression in AgRP neurons of CNO-treated hM3Dq-AgRP mice. Scale bar, 20mm. (e–h) Quantiﬁcation of confocal
images shown in a–d. The percentage of DREADD-positive (pos.) neurons (as assessed by GFP staining or mCherry ﬂuorescence) staining positive for
pCREB or c-fos was calculated. Data are expressed as means±s.e.m. (12–16 sections from three different mice per group were analysed). **Po0.01
(Student’s t-test).
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We next injected GsD-AgRP mice with either CNO alone
(0.5mg i.c.v.) or with CNO plus BIBO3304 (0.5 and 3 mg i.c.v.,
respectively). BIBO3304 treatment had no signiﬁcant effect on
CNO-induced food intake at the 0.5, 1 and 2 h time points but
caused a partial reduction in food intake 4 h after CNO injection
(Fig. 5a). This observation suggests that NPY does not make a
major contribution to the orexigenic effect caused by activation of
the GsD designer receptor in AgRP neurons.
To test the possibility that GABA release from AgRP neurons
might contribute to the ability of CNO to increase food intake in
GsD-AgRP mice, we generated GsD-AgRP mice that selectively
lacked the vesicular GABA transporter (Vgat) in AgRP neurons
(GsD-AgRP-ires-Cre, Vgatﬂox/ﬂox mice). In these mice, GABA
cannot be released from AgRP neurons since it cannot be packaged
in synaptic vesicles. We found that selective deletion of the Vgat
gene in AgRP neurons had no signiﬁcant effect on the ability of
CNO (1mgkg 1 i.p.) to stimulate food intake in GsD-AgRP mice
(Fig. 5b). This observation indicates that the orexigenic effect
triggered by activation of the GsD designer receptor in AgRP
neurons does not require the release of GABA.
GsD activation promotes hypothalamic AgRP release. To
further conﬁrm that activation of GsD expressed by AgRP
neurons promotes hypothalamic AgRP release, we carried out
ex vivo AgRP secretion experiments. Speciﬁcally, we incubated
hypothalamic slices prepared from GsD-AgRP mice, with
artiﬁcial cerebrospinal ﬂuid (aCSF) for 1 h at 37 C (to determine
basal AgRP release), followed by a second 1-h incubation in the
presence of CNO (15 mM). In parallel, we carried out analogous
experiments with hypothalamic slices prepared from mCherry-
AgRP control mice (AgRP-ires-Cre mice that had been injected
bilaterally with the AAV-hSyn-DIO-mCherry virus). Strikingly,
CNO triggered a signiﬁcant increase in AgRP release from
hypothalamic preparations of GsD-AgRP mice (Fig. 6a).
This effect was absent in hypothalamic slices prepared from
mCherry-AgRP control mice (Fig. 6b). Taken together, these data
clearly indicate that activation of GsD, a Gs-coupled designer
receptor, in AgRP neurons stimulates hypothalamic AgRP
release.
GsD activation increases AgRP and KLF4 expression. After
having demonstrated that AgRP is essential for the GsD-mediated
increases in food intake, we next examined whether hypothalamic
AgRP expression levels were altered in CNO-treated GsD-AgRP
mice. Speciﬁcally, we injected GsD-AgRP mice with CNO
(1mg kg 1 i.p) and prepared hypothalamic RNA 2 h later.
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Figure 3 | Food intake studies with GsD-AgRP, hM3Dq-AgRP and WT control mice. CNO-mediated activation of GsD in AgRP neurons promotes food
intake both acutely (a) and over a 3-day period (b), and increases body weight (BW) (c). Measurements were carried after a single i.c.v. injection of either
saline or CNO (1 mg) into GsD-AgRP mice. CNO-induced activation of hM3Dq in AgRP neurons stimulates food intake acutely (d) but not chronically
(e). BW was increased only on day 1 (f). Measurements were carried after a single i.c.v. injection of either saline or CNO (1mg) into hM3Dq-AgRP mice.
(g–i) Treatment of WTcontrol mice with an active AgRP fragment (AgRP83–132) promotes food intake acutely (g) and over a 3-day period (h), and leads to
increased BW (i). Measurements were carried out after a single i.c.v. injection of either saline or AgRP83–132 (3 mg). Injections were carried out
between 9:00 and 10:00. All experiments were carried out with 12- to 16-week-old male mice. Data are given as means±s.e.m. (n¼4–7 mice per group).
*Po0.05, **Po0.01, ***Po0.001, as compared with the corresponding saline-injected group (Student’s t-test).
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For control purposes, we carried out similar experiments with
hM3Dq-AgRP mice. We found that CNO treatment of
GsD-AgRP mice led to a robust (B2.5-fold) increase in
hypothalamic AgRP expression, as compared with saline-injected
GsD-AgRP control mice (Fig. 7a). In contrast, under the same
experimental conditions, hypothalamic AgRP expression levels
remained unchanged in hM3Dq-AgRP mice (Fig. 7a). Hypotha-
lamic NPY expression was not signiﬁcantly affected by CNO
treatment of either GsD-AgRP or hM3Dq-AgRP mice (Fig. 7a),
indicating that activation of GsD in AgRP neurons selectively
upregulates AgRP transcript levels.
Kru¨ppel-like factor 4 (KLF4) is a zinc ﬁnger transcription
factor, which is expressed in various tissues and modulates
many developmental processes and biological functions30,31.
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Figure 6 | Activation of GsD expressed by AgRP neurons promotes
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control mice. All experiments were carried out with 10- to 16-week-old
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Interestingly, recent studies have shown that drugs that increase
intracellular cAMP levels promote KLF4 expression in different
cell types32,33, indicative of a possible link between enhanced Gs
signalling and increased KLF4 expression. Moreover, Ilnytska
et al.34 recently demonstrated that KLF4 is a potent activator
of the AgRP promoter. We therefore speculated that activation
of the GsD designer receptor in AgRP neurons might lead to an
increase in hypothalamic KLF4 expression. In agreement with
this hypothesis, we found that CNO treatment (1mg kg 1 i.p) of
GsD-AgRP mice resulted in a signiﬁcant increase in
hypothalamic KLF4 expression levels (by B50%, as compared
with saline-injected control mice; hypothalamic RNA was
prepared 2 h after CNO injections; Fig. 7a). In contrast, CNO
treatment of hM3Dq-AgRP mice did not lead to an increase but
rather a reduction in hypothalamic KLF4 expression levels
(Fig. 7a).
To investigate whether the GsD-mediated stimulation of KLF4
mRNA expression also led to increased levels of KLF4 protein, we
microinjected the AAV-hSyn-DIO-GsD-eGFP virus unilaterally
into the ARC of AgRP-ires-Cre mice (right side), leading to
the expression of the GsD designer receptor in AgRP neurons of
the AAV-injected side only (Fig. 7b). Treatment of the
AAV-injected mice with CNO (1mg kg 1 i.p.) resulted in a
robust increase in KLF4 protein expression in AgRP neurons
expressing the GsD receptor, measured 1 h after CNO
administration (Fig. 7b, right side). Only weak KLF4 staining
was detected on the side that did not express the GsD receptor
(Fig. 7b, left side).
KLF4 overexpression in AgRP neurons promotes food intake.
To demonstrate that overexpression of KLF4 in AgRP neurons
promotes food intake, we injected the AAV-hSyn-DIO-KLF4
virus bilaterally into the ARC of AgRP-ires-Cre mice, resulting in
the selective expression of KLF4 in AgRP neurons (Fig. 7d).
Strikingly, the AAV-hSyn-DIO-KLF4-injected mice (KLF4-AgRP
mice) consumed signiﬁcantly more food than the control mice
injected with the AAV-hSyn-DIO-mCherry control virus
(Fig. 7e).
GsD-mediated increase in AgRP expression requires KLF4. We
next studied whether enhanced KLF4 expression is required for
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the observed GsD-mediated increase in AgRP transcription.
To test this hypothesis, we took advantage of the availability of a
compound called kenpaullone (Ken), a suppressor of KLF4
transcription35. Consistent with our hypothesis, we found that
pretreatment of GsD-AgRP mice with Ken (2 mg i.c.v.) led to a
pronounced reduction in CNO-mediated increases in both KLF4
and AgRP hypothalamic expression levels (Fig. 7c). In this ﬁgure,
gene expression levels are displayed normalized relative to those
obtained with CNO-treated GsD-AgRP mice that had been
pretreated with i.c.v. saline rather than Ken. Ken pretreatment
had no signiﬁcant effect on hypothalamic NPY expression levels
in CNO-injected GsD-AgRP mice (Fig. 7c). These data support
the concept that GsD-mediated stimulation of AgRP expression
requires an increase in KLF4 activity.
The KLF4 promoter is a direct target of activated CREB. To
examine whether the KLF4 promoter is directly activated by
CREB, we carried out a series of KLF4 promoter–luciferase
reporter assays (Supplementary Fig. 6a). The mouse KLF4
promoter contains two half CREB-responsive element (CRE) sites
(CGTCA) that form a cluster within 300 nucleotides upstream of
the transcription start (Supplementary Fig. 6c)36. We found that
mutational modiﬁcation of the ﬁrst half CRE site ( 269 site) had
no signiﬁcant effect on forskolin-mediated stimulation of KLF4
promoter activity. In contrast, mutation of the second half CRE
site ( 232 site) or of both half CRE sites virtually abolished this
response (Supplementary Fig. 6b), indicating that only the second
half CRE site is transcriptionally relevant. Taken together, these
data strongly suggest that the KLF4 promoter is a direct target of
activated CREB.
PAC1 receptors promote KLF4-dependent AgRP expression.
We next examined whether stimulation of endogenously
expressed Gs-coupled receptors resulted in cellular actions similar
to those observed with the GsD designer receptor. Initially, we
carried out studies with hypothalamic GT1-7 cells37, which are
known to release AgRP depending on their energy status38. We
found that incubation of GT1-7 cells with forskolin (10 mM) led
to a time-dependent increase in the expression of both AgRP and
KLF4 (Supplementary Fig. 7). These forskolin-induced effects
could be completely blocked by pretreatment of cells with the
PKA inhibitor, H89 (Supplementary Fig. 7), strongly suggesting
that cAMP-mediated activation of PKA promotes AgRP and
KLF4 expression.
GT1-7 cells express various Gs-linked GPCRs, including the
PAC1 receptor, a pituitary adenylate cyclase-activating peptide
(PACAP) receptor subtype39,40. We therefore treated GT1-7 cells
with PACAP1–38 (1 mM) to stimulate endogenously expressed
PAC1 receptors. PACAP1–38, similar to forskolin, triggered
pronounced increases in the expression of both AgRP and KLF4
(Fig. 8a,b). These effects were not observed in the presence of
H89, indicating that the stimulatory effects of PACAP1–38
on AgRP and KLF4 expression were due to receptor-mediated
stimulation of the Gs-cAMP-PKA cascade. Interestingly,
treatment of GT1-7 cells with Ken, an inhibitor of
KLF4 transcription (Fig. 8d), completely abolished the
PACAP1–38-induced increase in AgRP expression (Fig. 8c).
These results support the concept that PACAP1–38 induces
AgRP transcription in a KLF4-dependent manner.
PAC1 receptors stimulate AgRP expression and food intake.
Recent work has shown that AgRP neurons, like GT1-7 cells,
express PAC1 receptors21,41. The potential role of these receptors
in regulating food intake remains unclear. On the basis of our
ﬁndings obtained with CNO-treated GsD-AgRP mice, we tested
the hypothesis that selective activation of PAC1 receptors
endogenously expressed by AgRP neurons might cause a
sustained increase in food intake.
To stimulate these receptors in vivo, we took advantage of the
recent ﬁnding that PACAP-containing glutamatergic neurons in
the paraventricular nucleus of the hypothalamus (PVN) are
monosynaptically connected to AgRP neurons21. To selectively
activate this neuronal pathway, we ﬁrst injected the AAV-hM3Dq
virus (AAV-hSyn-DIO-hM3Dq-mCherry) into the PVN of
PACAP-ires-Cre mice (bilateral injections; use of ‘Flex Switch’
technology). This strategy resulted in the selective expression of
the hM3Dq designer receptor in PACAP neurons of the PVN21.
For the sake of brevity, we refer to these mice as hM3Dq-PACAP
mice. To activate the hM3Dq-expressing PACAP neurons in vivo,
we injected hM3Dq-PACAP mice with a single dose of CNO
(1mg kg 1 i.p.). Before CNO injections, hM3Dq-PACAP mice
received an i.c.v. injection of either saline or PACAP6–38 (1.2 mg),
a potent PAC1 receptor antagonist. CNO treatment of
hM3Dq-PACAP mice pre-injected with saline resulted in a
robust, time-dependent increase in acute food take (Fig. 9a).
Strikingly, this response was greatly reduced in CNO-injected
hM3Dq-PACAP mice that had been pretreated with PACAP6–38
(Fig. 9a). PACAP6–38 had no signiﬁcant effect on food intake in
WT mice (Supplementary Fig. 8).
We next examined whether CNO treatment of
hM3Dq-PACAP mice resulted in changes in the hypothalamic
transcript levels of AgRP, KLF4 and NPY. Speciﬁcally, hM3Dq-
PACAP mice that had been pretreated i.c.v. with either saline or
PACAP6–38 (1.2mg) were injected with CNO (1mg kg 1 i.p.),
and hypothalami were isolated and processed for quantitative
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Figure 8 | PACAP promotes AgRP expression in a KLF4-dependent
manner. (a,b) Effect of PACAP1–38 (1 mM) on AgRP (a) and KLF4 (b) mRNA
expression in GT1-7 cells. GT1-7 cells were incubated for 2 h at 37 C with
PACAP1–38, either in the absence or presence of H89 (75mM), a PKA
inhibitor. (c,d) Effects of Ken, an inhibitor of KLF4 expression, on
PACAP1–38-induced increases in AgRP (c) and KLF4 (d) expression in GT1-7
cells. GT1-7 cells were incubated for 2 h at 37 C with either PACAP1–38
(1 mM), PACAP1–38 plus Ken (5 mM) or Ken alone (5 mM). Data are given as
means±s.e.m. (n¼ 3 or 4). *Po0.05, **Po0.01, ***Po0.001, as
compared with the PACAP1–38-treated group (a,b, Student’s t-test; c,d,
one-way analysis of variance followed by Dunnett’s post hoc test).
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reverse transcription–PCR studies 2 h later. In the absence of
PACAP6–38, CNO treatment led to signiﬁcant increases in
hypothalamic AgRP and KLF4 expression levels, which were
similar in magnitude to those observed with CNO-treated
GsD-AgRP mice (Fig. 9b). In contrast, in hM3Dq-PACAP mice
that had been pretreated with PACAP6–38, CNO-induced AgRP
and KLF4 expression (but not NPY expression) was signiﬁcantly
suppressed (Fig. 9b). These results suggest that activation of PAC1
receptors endogenously expressed by AgRP neurons promotes
food intake by stimulating the KLF4-AgRP axis.
Finally, we investigated whether CNO treatment of hM3Dq-
PACAP mice had long-lasting effects on food intake, as observed
with CNO-injected GsD-AgRP mice. We found that a single
injection of CNO (1mg kg 1 i.p.) stimulated food intake for 3
days, similar to the results obtained with GsD-AgRP mice
(Figs 3b and 9c). The long-lasting stimulatory effect of CNO on
food intake was accompanied by an increase in body weight (note
that this effect was highly signiﬁcant on day 3 after CNO
injection; Fig. 9d). Taken together, these data strongly suggest
that activation of PAC1 receptors endogenously expressed by
AgRP neurons mimics the sustained orexigenic effect triggered by
GsD signalling in these neurons.
Fasting promotes pCREB expression in AgRP neurons. To
explore whether Gs-pCREB signalling in AgRP neurons is
sensitive to altered metabolic conditions such as fasting when
AgRP neurons show increased activity, we studied pCREB
expression in AgRP neurons of Npy-hrGFP mice (Npy-GFP
mice)42. This mouse line expresses GFP selectively in NPY/AgRP
neurons42. Speciﬁcally, we prepared hypothalamic sections
from Npy-GFP mice that had either free access to food or had
been fasted for 20 h. AgRP neurons were identiﬁed by
GFP ﬂuorescence (green) while pCREB expression was probed
with an anti-pCREB antibody (red ﬂuorescence; Fig. 10 and
Supplementary Fig. 9).We found that fasted mice showed a
marked increase in the number of AgRP neurons staining positive
for pCREB (Fig. 10c). This observation suggests that pCREB
expression in AgRP neurons is likely to be of physiological
relevance.
Discussion
Food intake studies showed that treatment of GsD-AgRP mice
with a single dose of CNO resulted in a long-lasting (for several
days) orexigenic effect that was associated with a signiﬁcant
increase in body weight (Fig. 3a–c). In contrast, the stimulatory
effect observed with CNO-treated hM3Dq-AgRP mice lasted
only for a single day (Fig. 3d–f), most likely reﬂecting differences
in cellular activity caused by the activation of Gs- versus
Gq-dependent signalling pathways (Figs 1c and 2).
AgRP neurons store and release the neuropeptides AgRP and
NPY, as well as the biogenic amine, GABA, all of which promote
food intake4. Using a combined genetic/pharmacological
approach, we demonstrated that NPY and GABA release do
not contribute to a signiﬁcant extent to the orexigenic effects
mediated by the GsD designer receptor expressed by AgRP
neurons (Fig. 5). In contrast, the GsD-mediated increase in food
intake was completely abolished by i.c.v. treatment of GsD-AgRP
mice with an anti-AgRP antibody (Fig. 4c). These data clearly
indicate that the ability of the Gs-coupled designer receptor to
promote food intake is mediated by the release of AgRP.
In striking contrast, the anti-AgRP antibody had no signiﬁcant
effect on the CNO-induced increase in food intake observed with
hM3Dq-AgRP mice (Fig. 4d). In agreement with this observation,
Krashes et al.5 recently reported that the release of either NPY or
GABA alone is sufﬁcient to drive acute feeding in CNO-treated
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Figure 9 | Selective activation of PVN-PACAP neurons mimics the
phenotypes displayed by CNO-treated GsD-AgRP mice. All studies were
carried out with mice selectively expressing hM3Dq in PACAP neurons
of the PVN of PACAP-ires-Cre mice (hM3Dq-PACAP mice; see ref. 21).
(a) PACAP6–38, a PACAP receptor antagonist, inhibits CNO-induced acute
food intake in hM3Dq-PACAP mice. Mice initially received an i.c.v. injection
of either saline or PACAP6–38 (1.2 mg). Thirty minutes later, all mice were
injected with CNO (1mg kg 1 i.p.). (b) Activation of PVN-PACAP neurons
promotes hypothalamic AgRP and KLF4 expression. hM3Dq-PACAP mice
were injected (i.c.v.) with either saline or PACAP6–38 (1.2 mg). Thirty
minutes later, all mice were treated with CNO (1mg kg 1 i.p.).
Hypothalamic RNA was isolated and processed for quantitative reverse
transcription–PCR studies 2 h after CNO treatment. Expression data were
normalized relative to the results obtained with CNO-treated GsD-AgRP
mice. (c,d) Activation of PVN-PACAP neurons leads to long-lasting
increases in food intake and increased body weight (BW). hM3Dq-PACAP
mice received a single i.p. injection of either saline or CNO (1mg kg 1).
Changes in BW were expressed relative to pre-injection values (¼ 100%).
(e) Scheme summarizing the cellular pathway through which agonist-
activated Gs-coupled GPCRs expressed by AgRP neurons are predicted to
promote appetite. All experiments were carried out with 10- to 16-week-old
male mice. Data are given as means±s.e.m. (n¼ 3–6 mice per group).
*Po0.05, **Po0.01, as compared with the corresponding control group
(Student’s t-test).
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hM3Dq-AgRP mice and that AgRP does not contribute to this
response.
Given the key role of AgRP in mediating the orexigenic effects
displayed by CNO-treated GsD-AgRP mice, we speculated that
CNO stimulation of GsD might affect AgRP expression.
Consistent with this hypothesis, CNO treatment of GsD-AgRP
mice resulted in a robust increase in hypothalamic AgRP
transcript levels (Fig. 7a). In contrast, hypothalamic
AgRP expression remained unaffected in CNO-injected
hM3Dq-AgRP mice (Fig. 7a). It is likely that the increase in
GsD-mediated AgRP expression represents a key factor
contributing to the long-lasting orexigenic effects observed with
CNO-treated GsD-AgRP mice.
Since drugs that enhance the production of cAMP can
stimulate KLF4 expression in different cell types32,33, we tested
the hypothesis that GsD-mediated stimulation of KLF4
expression is required for the GsD-dependent increase in AgRP
levels observed with GsD-AgRP mice. We ﬁrst showed that CNO
treatment of GsD-AgRP mice led to a signiﬁcant increase in
hypothalamic KLF4 mRNA levels and a pronounced increase in
KLF4 protein levels in AgRP neurons expressing the GsD
designer receptor (Fig. 7a,b). Studies with a chemical inhibitor
of KLF4 transcription35 indicated that the GsD-mediated increase
in hypothalamic AgRP expression requires KLF4 (Fig. 7c).
Importantly, overexpression of KLF4 in AgRP neurons led to a
signiﬁcant increase in food intake (Fig. 7d,e). Taken together,
these data strongly support the concept that activation of the
Gs-linked designer receptor (GsD) promotes food intake by
stimulating KLF4-dependent expression of AgRP.
Studies with cultured hypothalamic cells demonstrated that
ligand-induced activation of an endogenously expressed
Gs-linked receptor, the PAC1 receptor subtype, also promoted
KLF4 and AgRP expression, similar to the ﬁndings obtained
with CNO-treated GsD-AgRP mice. Additional studies
indicated that these responses were PKA dependent and that
increases in KLF4 expression triggered the upregulation of
AgRP expression (Fig. 8). Collectively, these data strongly
support the concept that activation of Gs-coupled receptors
endogenously expressed by AgRP neurons (for example, PAC1
receptors) stimulates a PKA-dependent signalling cascade that
promotes the expression of KLF4 and AgRP in a sequential
fashion (Fig. 9).
A recent study43 reported that overexpression of KLF4 in the
ARC of rats abolished the anorectic actions of leptin. Taken
together, these ﬁndings indicate that KLF4 represents an
important central regulator of the activity of hypothalamic
AgRP neurons.
In agreement with the in vitro studies, in vivo experiments
demonstrated that the activation of Gs-linked PAC1 receptors
endogenously expressed by AgRP neurons closely mimicked
the stimulatory effects on food intake and body weight
observed with CNO-treated GsD-AgRP mice (Figs 3 and 9). In
this set of experiments, we used a chemogenetic strategy to
selectively activate the PACAP-containing neurons of the PVN
that are monosynaptically connected to AgRP neurons21.
Importantly, the increase in food intake observed after
activation of this pathway could be greatly reduced by
pretreatment of mice with PACAP6–38, a PAC1 receptor
antagonist (Fig. 9a). These data strongly support the concept
that stimulation of PAC1 receptors or other Gs-coupled receptors
endogenously expressed by AgRP neurons leads to a sustained
increase in food intake (Fig. 9e). Interestingly, microarray data
have shown that AgRP neurons express additional Gs-coupled
GPCRs, besides the PAC1 receptor, including calcitonin and MC3
melanocortin receptors (Geo dataset GSE45858; also see ref. 44).
It is likely that signalling through all of these receptors
contributes to Gs-mediated AgRP release.
As pointed out at the beginning of the Discussion section,
CNO treatment did not depolarize GsD-AgRP neurons in ex vivo
whole-cell patch clamp experiments (Fig. 1c,d). However, this
ﬁnding does not exclude the possibility that CNO-mediated
stimulation of GsD affects the activity of downstream signalling
molecules and/or ion channels that facilitate the activation of
AgRP neurons in vivo where these neurons are exposed to a
multitude of hormones and neurotransmitters. Consistent with
this concept, activation of the Gs-cAMP signalling pathway by
Gs-coupled receptors has been shown to promote neuronal
excitability45–47. It is likely that the sustained orexigenic
effect observed with CNO-treated GsD-AgRP mice is due to
cAMP-PKA-mediated changes at the transcriptional level
(Figs 7–9) and/or Gs-dependent changes in synaptic plasticity48,
which remain to be explored.
Our ﬁndings raise the possibility that drugs that block the
activity of Gs-coupled receptors endogenously expressed by AgRP
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Figure 10 | Fasting-induced increase in pCREB expression in AgRP neurons of the ARC. (a) Representative confocal images of hypothalamic sections
obtained from Npy-GFPmice after a 20-h fast. pCREB-expressing cells are visualized by an anti-pCREB antibody (red stain, left panel). AgRP (NPY)-positive
neurons are visualized by green GFP ﬂuorescence (centre panel). The right panel represents a merged image indicating that most AgRP neurons are pCREB
positive. (b) Images corresponding to the ones shown in a were obtained with freely fed Npy-GFP mice, indicating a striking reduction in pCREB-positive
AgRP neurons. (c) Quantiﬁcation of confocal images. The percentage of AgRP-positive neurons (as assessed by GFP ﬂuorescence) staining positive for
pCREB was calculated. Data are expressed as means±s.e.m. (13–17 sections from three different adult male mice per group were analysed). **Po0.01
(Student’s t-test). Scale bar, 20mm.
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neurons or that interfere with Gs-dependent downstream
signalling pathways might become useful as appetite-suppressing
drugs. The identiﬁcation of the complete set of GPCRs expressed
by AgRP neurons under physiological and pathophysiological
conditions should provide a rational basis for this approach.
Methods
Mice. The generation of AgRP-ires-Cre mice (ref. 49), PACAP-ires-Cre (ref. 21),
Vgatﬂox/ﬂox (ref. 49), NPY-hrGFP (ref. 42) and Agrp-ires-Cre; R26-loxSTOPlox-
L10-GFP (L10-GFP mice21) has been described previously. In L10-GFP mice, eGFP
fused to the L10-ribosomal subunit is selectively expressed, in a Cre-dependent
fashion, in AgRP neurons21. Ay mice (strain name: B6.Cg-Ay/J; stock number:
000021) were purchased from the Jackson Laboratory (Bar Harbor, ME). All
experiments were conducted according to the US National Institutes of Health
Guidelines for Animal Research and were approved by the NIDDK Institutional
Animal Care and Use Committee.
Mouse maintenance and diet. Mice were fed ad libitum and kept on a 12-h light,
12-h dark cycle. Unless stated otherwise, all experiments were carried out with
male littermates that were 10–16 weeks old and maintained on a standard NIH
mouse chow (B4% (w/w) fat content).
Generation of AAV-hSyn-DIO vectors. The generation of the AAV-hSyn-DIO-
hM3Dq-mCherry and AAV-hSyn-DIO-mCherry viral vectors has been described
previously19. To generate the AAV-hSyn-DIO-GsD-eGFP vector, we replaced the
hM3Dq-mCherry coding sequence in the pAAV-hSyn-DIO hM3Dq-mCherry
plasmid (a kind gift by Dr Bryan Roth, UNC, Chapel Hill, NC) with the HA-GsD-
eGFP coding sequence14. The AAV-hSyn-DIO-rM3D(Gs)-mCherry virus was
provided by the UNC Vector Core (Chapel Hill, NC). This latter virus is identical
with the AAV-hSyn-DIO-GsD-eGFP virus except for the different ﬂuorescence
tags (mCherry versus eGFP, respectively). To generate the AAV-hSyn-DIO-KLF4
vector, we ﬁrst fused the human inﬂuenza hemagglutinin (HA) tag sequence to the
KLF4 coding sequence (Addgene plasmid #15920) by using a PCR strategy. Then,
the KLF4-HA coding sequence was cloned into the pAAV-hSyn-DIO vector. All
AAVs were packaged in serotype 8 by the UNC Vector Core.
Stereotaxic injections. Male mice that were at least 6 weeks old were anaes-
thetized with isoﬂurane, and placed into a stereotaxic apparatus (David Kopf
Instruments, model 940A with 923B mouse gas aesthesia head holder). The skull
was exposed via a small incision and a small hole was drilled (0.45-mm drill bit)
into the skull for the injection of AAVs. A Hamilton 10-ml syringe with a 30- or
33-gauge blunt-end needle was inserted into the brain for virus delivery. Post-
operative analgesia was provided (ketoprofen, 5mg kg 1 subcutaneous). Bilateral
injections (200 nl of AAV) were made in the ARC. The coordinates were
(from bregma) as follows: anterior–posterior,  1.46mm; lateral (from midline),
±0.3mm; dorsal–ventral,  5.80mm). In a similar fashion, bilateral injections
were made in the PVN. The coordinates were (from bregma) as follows:
anterior–posterior,  0.82mm; lateral (from midline), ±0.25mm; dorsal–ventral,
 4.80mm (from the surface of the skull). Mice were allowed to recover for 10
days before the start of feeding experiments.
Immunohistochemistry and imaging studies. Mice were perfused with 4%
paraformaldehyde in 0.1M phosphate buffer ﬁxative (pH 7.4). Tissue was
post-ﬁxed in this solution overnight and transferred to 20% sucrose in 1 PBS.
Hypothalamic slices (20–30-mm thick) were incubated overnight at 4 C with
primary antibodies diluted in PBS, supplemented with 1% BSA and 0.1% Triton
X-100. Slices were then washed three times and incubated with ﬂuorophore-con-
jugated secondary antibodies for 2 h at room temperature. Slices were rinsed three
times in PBS containing 0.1% Triton X-100 and then mounted for imaging using
Antifade Reagent (SlowFade Gold with DAPI, S36939; Life Technologies, Grand
Island, NY) or Vectashield technology (Vector Labs, Burlingame, CA).
Fluorescence images were taken with a Zeiss Imager D1 ﬂuorescent microscope
and a Zeiss LSM-700 confocal microscope.
Quantiﬁcation of c-fos and pCREB expression. To quantitate CNO-induced
changes in c-fos and pCREB expression in DREADD-expressing AgRP neurons or
changes in pCREB expression in AgRP neurons of fed and fasted Npy-GFP mice42,
we carried out a series of immunohistochemical studies. CNO (1mg kg 1)-
injected GsD-AgRP and hM3Dq-AgRP mice were killed 2 h after drug treatment.
For fasting experiments, Npy-GFP mice were killed at 9:00 in either the ad lib fed
state or after a 20-h fast (food was removed at 12:00 on the previous day).
Hypothalamic sections were prepared and processed for immunohistochemical
staining as described above. AgRP neurons/DREADD-expressing AgRP neurons
staining positive for pCREB or c-fos were visualized and counted using confocal
images taken under  20 and  40 power of magniﬁcation. Fluorescent images
were captured using a Zeiss LSM-700 confocal microscope. Cells were counted by
an observer that was blinded to mouse treatment or genotype of the mice. Data are
expressed as the percentage of all AgRP neurons staining positive for pCREB
(experiments with Npy-GFP mice) or as the percentage of DREADD-expressing
AgRP neurons staining positive for pCREB or c-fos, respectively. The antibodies
used are listed in Supplementary Table 2.
I.c.v. injections. For i.c.v. injections of drugs or antibodies, mice were anaes-
thetized with 2–3% isoﬂurane and placed into a stereotaxic apparatus (see
‘Stereotaxic injections’). The surface of the skull was exposed with sterile surgical
instruments, and a small hole was drilled through the skull and a guide cannula was
placed into the lateral ventricle via the stereotaxic manipulator. For i.c.v. injections,
the following coordinates were used (from bregma): anterior–posterior,
 0.34mm; lateral (from midline), þ 1mm; dorsal–ventral,  2.3mm (from the
surface of the skull). The guide cannula (Plastic One; C315GS-2/SP, 2.6mm with
2mm pedestal; Roanoke, VA) was placed and secured using Loctite 454 Glue. After
a 2-week recovery period, a small injection cannula (Plastic One; C315IS-2/SPC, ﬁt
2.6mm C315GS-2 with 1mm projection) attached to a catheter and a Hamilton
syringe was inserted into the guide cannula. The injection cannula protruded 1mm
beyond the end of the guide cannula into the ventricle. Drugs or antibodies were
delivered slowly in a 2-ml volume via the injection cannula. After an additional
7min, the injection cannula was removed and capped with a dummy cannula
(C315FDS-2; Plastic One). The following drugs or antibodies were delivered via
this route: AgRP83–132 (1mg; Phoenix Pharmaceuticals), anti-AgRP puriﬁed IgG
antibody (3mg; Phoenix Pharmaceuticals), BIBO3304 (3.3 mg; Tocris, MO), CNO
(0.1, 0.3, 0.5 or 1 mg), kenpaullone (2 mg; Sigma-Aldrich), NPY (0.85 mg; Phoenix
Pharmaceuticals) and PACAP6–38 (1.2 mg; Phoenix Pharmaceuticals).
Assessment of neuropeptide and KLF4 mRNA levels. AgRP, KLF4 and NPY
mRNA levels were measured using RNA prepared from cultured GT1-7 cells or
from mouse hypothalamic tissue. One day before the assay, GT1-7 cells were
seeded into six-well plates at a density of 1 106 cell per dish and cultured in
DMEM containing 10% fetal bovine serum and penicillin (100 units per ml)/
streptomycin (100 mgml 1) in a humidiﬁed atmosphere of 5% CO2/95% O2 at
37 C. On the day of the assay, the medium was replaced with fresh DMEM. One
hour later, GT1-7 cells were incubated for 2 h at 37 C with the following com-
pounds (ﬁnal concentrations): PACAP1–38 (1mM; Phoenix Pharmaceuticals), H89
(75 mM; Sigma-Aldrich) or kenpaullone (5 mM; K3888, Sigma-Aldrich). Total RNA
was then isolated using the RNeasy Mini Kit (Qiagen) and treated with DNase I for
15min at 30 C. Reverse transcription was performed using the SuperScript III ﬁrst
strand synthesis kit (Invitrogen) and gene expression levels were measured by
monitoring SYBR green ﬂuorescence intensity over time using a Bio-Rad CFX96
Real Time System C1000 Touch Thermal Cycler (Bio-Rad). Each PCR reaction
(ﬁnal volume: 20ml) consisted of cDNA (1 mg of initial RNA sample), 10 ml of SYBR
Green PCR Master Mix (Applied Biosystems) and 100 nM of each PCR primer. For
each primer pair, quantitative reverse transcription–PCR reactions were performed
in duplicate using a 96-well plate format. Primers for b-actin, AgRP, KLF4 and
NPY were selected from previously validated primer sets (see table below). PCR
cycling conditions were as follows: 50 C for 2min, 95 C for 10min; and 40 cycles
at 95 C for 15 s and 60 C for 1min, respectively. The expression of b-actin RNA
served as an internal control. The results were expressed as fold change in
expression of a particular RNA transcript relative to b-actin RNA expression
between untreated and drug-treated cells.
In some experiments, AAV-injected mice (hM3Dq-AgRP, GsD-AgRP or
hM3Dq-PACAP mice) were injected i.p. with saline or CNO (1mg kg 1). In a
subset of experiments, i.c.v. injections of kenpaullone or PACAP6–38 were
performed 30–45min before i.p. saline or CNO injections. Two hours after the
administration of CNO (or saline), RNA was extracted from mouse hypothalami
using the QIAzol Lysis reagent (Qiagen). cDNA synthesis and qPCR studies were
performed as described in the previous paragraph. Experimental data were
expressed as fold change in expression of a particular RNA transcript relative to
b-actin RNA expression between a speciﬁc test group and the corresponding
control group (for primer sequences, see Supplementary Table 3).
Electrophysiology. To obtain brain slices that contain the ARC, mice (age: B10
weeks) were decapitated under isoﬂurane anaesthesia, and brains were rapidly
removed and placed in ice-cold sucrose aCSF (composition in mM): 194 sucrose,
20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose and 26.0 NaHCO3,
saturated with 95% O2/5% CO2 gas. The 300-mm sections were sliced using a Leica
VT1000 vibratome (Wetzlar, Germany).
For whole-cell patch clamp electrophysiological recordings, brain slices
containing the ARC were incubated at B30 C in a heated, oxygenated holding
chamber containing aCSF (composition in mM): 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2
MgSO4, 1 NaH2PO4, 10.0 glucose and 26.0 NaHCO3, and then transferred to a
submerged recording chamber maintained at B30 C (Warner Instruments,
Hamden, CT). Recording electrodes (3–5MO) were pulled with a Flaming-Brown
Micropipette Puller (Sutter Instruments, Novato, CA) using thin-walled
borosilicate glass capillaries. These recording electrodes were ﬁlled with a solution
of the following composition (in mM): 135 Kþ -gluconate, 5 NaCl, 2 MgCl2, 10
HEPES, 0.6 EGTA, 4 Na2APT and 0.4 Na2GPT. To block neural ﬁring,
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tetrodotoxin (0.5 mM) was added to the perfusing aCSF solutions described above.
Signals were acquired via a Multiclamp 700B ampliﬁer (Molecular Devices,
Sunnyvale, CA), digitized at 20 kHz, ﬁltered at 3 kHz and analysed using Clampﬁt
10.4 software (Molecular Devices). Input resistance and access resistance were
monitored before and after each experiment. Experiments in which changes in
access resistance were 420% were not included in the data analysis. A maximum
of two neurons were analysed per mouse. Membrane potential shift was
compared between a 4-min bin average during baseline and a 4-min bin average at
the end of drug application. NPY-hrGFP mice were used to visualize AgRP
neurons. In the case of GsD-AgRP and hM3Dq-AgRP mice, AgRP neurons were
identiﬁed by mCherry ﬂuorescence (both GsD and hM3Dq were fused to mCherry
at their C termini).
Food intake measurements. Mice (10- to 16-week-old males) were housed singly
for at least 1 week before food intake measurements. CNO or other drugs were
injected, either i.p. or i.c.v., between 9:00 and 10:00. After drug treatment, mice
were placed in new cages with 5–6 food pellets (2.5–4 g per pellet) of standard
mouse chow. Food intake was measured 0.5, 1, 2, 4, 24, 48 and 72 h after drug
injections.
Measurement of AgRP release from hypothalamic slices. The release of AgRP
from mouse hypothalamic slices was measured ex vivo, in a fashion similar to that
described by Enriori et al.50 The 2-mm-thick hypothalamic slices containing the
ARC and PVH were prepared from GsD-AgRP and mCherry-AgRP control
mice (AgRP-ires-Cre mice that had been injected bilaterally with the AAV-hSyn-
DIO-mCherry virus). The slices were then incubated in aCSF plus 1.7 ml ml 1 of
protease inhibitor cocktail (Sigma) and equilibrated with 95% O2 and 5% CO2 at
37 C for 1 h. Hypothalamic slices were then incubated for 1 h in aCSF to
determine basal AgRP release. Subsequently, slices were incubated for another 1 h
period in the presence of CNO (15mM). Tissue viability was veriﬁed by exposure to
56mM KCl for 1 h. Supernatants were collected, and AgRP concentrations were
determined using an AgRP ﬂuorescence EIA kit (Phoenix Pharmaceuticals)
according to the manufacturer’s protocol. The amount of AgRP secreted into the
medium in the presence of CNO was normalized to basal AgRP release determined
during the initial aCSF incubation period.
Generation of KLF4 promoter–luciferase reporter constructs. The pGL3–
pKLF4 luciferase reporter construct51 containing B1.5 kb of the mouse KLF4
promoter was kindly provided by Dr John Christman (The Ohio State University
Wexner Medical Center, Columbus, OH). The two half CRE sites (CGTCA)
present in the KLF4 promoter ( 269 to  265 and  232 to  228, respectively)
were mutated to CATGG (ref. 52) using the QuikChange Site-Directed
Mutagenesis Kit (Agilent). The correctness of all constructs was veriﬁed by
sequencing. The numbering of KLF4 promoter sequences is based on the
NM_010637 NCBI reference sequence.
Luciferase reporter assays. HEK293T cells were transfected with the pGL3–
pKLF4 reporter construct using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Where indicated, cells were transfected with the
pCMV–FLAG–ACREB construct (kindly provided by Dr Rebecca Berdeaux) or
pcDNA3.1 (empty vector) to adjust for the amount of transfected DNA. All cells
were co-transfected with the pACLA-RSV-b-Gal plasmid52, which served as
internal control to normalize the luminescence signal for transfection efﬁciency.
About 24 h after transfection, cells were incubated in 24-well plates for 5 h at 37 C
with forskolin (10 mM) or vehicle (DMSO), and luciferase assays were performed as
described previously53.
Statistical analysis. Data are expressed as means±s.e.m. for the indicated
number of observations. The statistical tests used are indicated in the ﬁgure
legends.
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